April 5, 2018 / 12:12 PM / 6 months ago

BRIEF-Vistagen Therapeutics Initiates Phase 2 Study Of AV 101 For Major Depressive Disorder

April 5 (Reuters) - VistaGen Therapeutics Inc:

* 101 FOR MAJOR DEPRESSIVE DISORDER

* LINE RESULTS FROM ELEVATE ARE EXPECTED IN FIRST HALF OF 2019 ​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below